AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04462562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative US (Samsung Medison, RS85A)
Description: In each patients, measurements of tissue attenuation imagine (TAI), tissue scatter-distribution imaging (TSI) parameters, hepatorenal index (EzHRI) will be performed
Study NCT01859832 — intervention group
Intervention type: OTHER
Intervention: Cylex ImmuKnow Assay
Description: This is not an interventional study. However the assay being tested on the samples of all enrolled participants in the Cylex ImmuKnow Assay
Study NCT04790877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-study 1
Description: Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).
Study NCT04790877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-study 1
Description: Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).
Study NCT04790877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-study 2
Description: Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.
Study NCT04790877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-study 2
Description: Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.
Study NCT05352204 — intervention group
Intervention type: PROCEDURE
Intervention: transcatheter arterial chemoembolization
Description: transcatheter arterial chemoembolization after liver resection
Study NCT02515110 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo hypofractionated RNI
Study NCT02515110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02515110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04329702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills training mobile app with call from CST therapist
Description: The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. A therapist will call participant to introduce the intervention and perform a brief relaxation exercise.
Study NCT04329702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills training mobile app only
Description: The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. App chat room access will be provided.
Study NCT01630473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy
Description: After a periodontal full flap is dissected, by using small round burs, vertical lines (2 mm depth corticotomy) parallel to each root of the teeth in the anterior segment (canines and incisors) are created 5 mm beyond the apex in the maxillary bones and interconnecting the lines at the apex by horizontal corticotomies. Marginal bone crest is not touched by the surgical procedure.
Study NCT01630473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orthodontics
Description: Conventional orthodontic treatment
Study NCT00533832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vagus nerve stimulation (VNS)
Description: intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase.
Study NCT00533832 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: vagus nerve stimulation (VNS)
Description: intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase.
Study NCT04122014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive balance training
Description: Progressive balance training program
Study NCT04122014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal daily activities
Description: Usual daily activities
Study NCT03915015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: MRI
Study NCT04543071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motixafortide
Description: 1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly
Study NCT04543071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg intravenous (IV) once every 21 days
Study NCT04543071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 IV on days days 1, 8, 14 (every 28 days)
Study NCT04543071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2 IV on days 1, 8, 14 (every 28 days)
Study NCT03005795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Headphones
Description: Music can be heard through headphones
Study NCT03005795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Headphones
Description: No Headphones will be used.
Study NCT00971451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: 20 minutes of knee joint cryotherapy - ice bag application
Study NCT00971451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: continuous use of TENS during the exercise session
Study NCT03100045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories
Description: Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
Study NCT00952497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Capecitabine, Telatinib
Description: Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
Study NCT03129321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Econazole Nitrate Cream, 1%
Study NCT03129321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole Nitrate Cream, 1%
Study NCT03129321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01971073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: arm Participants will receive bilateral anodal-left cathodal-right tDCS or anodal-right cathodal-left tDCS over the DLPFC.~The following parameters will be used: stimulation intensity of 2 milliAmps for 20 minutes (6 consecutive sessions ).
Study NCT01971073 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: the sham tDCS group. Neuropsychological testing and symptom ratings will be conducted at baseline and 4 weeks after the end of treatment
Study NCT02353156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic bidet
Description: electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing
Study NCT02353156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sitz bath
Description: sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
Study NCT00067028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine 40mg/m^2
Description: 40 mg/m\^2 by vein over 1 hour daily for 5 days.
Study NCT00067028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin 10mg/m^2
Description: 10 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Clofarabine + Idarubicin plus Ara-C:~6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
Study NCT00067028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C 0.75 g/m^2
Description: 0.75 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
Study NCT00067028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine 22.5mg/m^2
Description: 22.5 mg/m\^2 by vein over 1 hour daily for 5 days.
Study NCT00067028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C 1 g/m^2
Description: 1 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
Study NCT00067028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin 6 mg/m^2
Description: 6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
Study NCT02534402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administration of prednisone to determine the effect on whole blood gene expression.
Study NCT02789904 — intervention group
Intervention type: OTHER
Intervention: blood taking
Description: Blood taking will be done for chest pain patients presenting with chest pain at 0, 1 and 2 hour
Study NCT00916188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black Tea Extract
Description: Amount/dose depends on Arm assignment.
Study NCT00916188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black Tea Extract
Description: Amount/dose depends on Arm assignment.
Study NCT04531696 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Blood draw at inclusion
Study NCT04531696 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Post-mortem tissue collection
Description: Sample collection (both liquids, tumour tissue and non-tumour tissue) during post-mortem research autopsy
Study NCT00112671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally 400mg orally twice daily
Study NCT00112671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT06211894 — intervention group
Intervention type: PROCEDURE
Intervention: transobturator tape
Description: transobturator tape :The surgeon makes a small incision in the vagina and small incisions in the right and left groin. The surgical process is similar to the retropubic approach, but the mesh passes through the groin muscles rather than the abdominal wall. transperineal ultrasound: patients who underwent TOT and were evaluated with transperineal ultrasonography, women with incontinence 6 months after the surgery showed discrepancies in the movement of the urethra with the sling compared to continent women, along with asymmetry between the mesh arms, bladder neck descent, and varied sling positions.
Study NCT02253862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Description: administered days 8-18
Study NCT02253862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: administered days 8-18
Study NCT02104986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velbe-Bleomycin-Cisplatin
Description: Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects
Study NCT02104986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepeside-ifosfamide-Cisplatin
Study NCT02841397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Pulse CO-Oximeter
Description: Noninvasive pulse oximeter with various features for measurement of hemoglobin, pleth variability index, and oxygen reserve index
Study NCT05404464 — intervention group
Intervention type: OTHER
Intervention: Different baseline characteristics and clinical management
Description: Personal history, basic diseases, stimulation plan, type of ART, transplantation strategy, etc.
Study NCT02902250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression
Description: vertebral body decompression in compression fracture
Study NCT02902250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment
Description: Conservative Treatment in vertebral compression fracture
Study NCT02093806 — intervention group
Intervention type: OTHER
Intervention: measurment
Study NCT02757599 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound training
Description: Training on the transvaginal ultrasound simulator.
Study NCT02738970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
Study NCT02738970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
Study NCT02738970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
Study NCT02738970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
Study NCT03769246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upright Go Device
Description: Participants will be asked to use the Upright device everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
Study NCT03769246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ergonomic Handout
Description: Participants will be asked to use the ergonomic handout everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
Study NCT02343159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: 120 mg and 240 mg delayed release capsules
Study NCT02343159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Description: The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container
Study NCT02343159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence counseling
Description: A telephone call to discuss adherence and individualized strategies based on data collected via smart device (i.e., LCD reader)
Study NCT01647451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0006
Description: Two i.v. (intravenous) doses administered 6 weeks apart.
Study NCT01647451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Two i.v. (intravenous) doses administered 6 weeks apart.
Study NCT01147328 — intervention group
Intervention type: OTHER
Intervention: Virtual Health Record (VHR)
Description: Technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal.
Study NCT03703102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Description: Anti-OX40 Monoclonal Antibody KHK4083
Study NCT03703102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02458963 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Women will undergo one IVF cycle
Study NCT02458963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin
Description: Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
Study NCT03433872 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: We Grow Together: The Q-CCIIT Professional Development System
Description: We Grow Together is designed to strengthen high quality caregiver interactions with infants and toddlers. The starting point for the We Grow Together study is assessment of a caregiver's interactions with infants and toddlers in the caregiver's ECE setting, using the Q-CCIIT observational measure. Data from the Q CCIIT observations highlight areas for growth in the caregiver's practices and will inform a PD goal-setting process, with the help of a PD Provider. An array of We Grow Together materials targeting practices assessed by the Q-CCIIT measure and informed by professional development and behavior change research are organized into modules, and delivered on an interactive website. Over the course of a program year, each caregiver in the study will work with a PD provider who is trained in guiding caregivers through the use of We Grow Together materials.
Study NCT03633175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: 400 mg vaginal progesterone \[Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt\] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).
Study NCT03001089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Fludrocortisone (enteral)
Description: Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
Study NCT03001089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
Study NCT04542759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Besifloxacin Ophthalmic
Description: Prophylaxis for endophthalmitis
Study NCT04542759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution
Description: Placebo
Study NCT03814486 — intervention group
Intervention type: OTHER
Intervention: descriptive
Description: evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted
Study NCT04331795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP > 40mg/L
Study NCT04331795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP > 40mg/L
Study NCT02094456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic clipping of diverticula
Description: Colonoscopy with identification of each individual colonic diverticula and endoscopic clipping.
Study NCT02094456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Follow-up colonoscopy
Description: Patients will undergo a repeat colonoscopy 6 months after endoscopic clipping procedure.
Study NCT02483663 — intervention group
Intervention type: DEVICE
Intervention: Functional Magnetic Resonance Imaging
Description: Measure brain activity.
Study NCT02483663 — intervention group
Intervention type: RADIATION
Intervention: Dual Energy X-ray absorptiometry
Description: Body composition measurements.
Study NCT02483663 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.
Study NCT02483663 — intervention group
Intervention type: OTHER
Intervention: Mood and Appetite Ratings
Description: Answer questions about how you are feeling at the moment.